News
Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure
Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson, marking the latest twist in an unusual run leading the FDA office overseeing vaccines and gene therapy.
Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...
Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.
Makary and Prasad co-authored a paper in 2022 in the British Medical Journal, finding that COVID-19 booster mandates for teenagers and young adults did more harm than good, particularly causing ...
Dr. Vinay Prasad described the new approach as a “reasonable compromise” that will allow vaccinations in high-risk groups to continue while generating new data about whether they still benefit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback